FDA approves new ready-to-use romidepsin injection for lymphoma treatment.

The U.S. Food and Drug Administration has granted approval for Amneal Pharmaceuticals' romidepsin injection solution, a new ready-to-use formulation. This drug is indicated for adults with cutaneous T-cell lymphoma who have undergone at least one prior systemic therapy. The ready-to-use format is expected to offer safety and operational benefits by simplifying preparation steps for healthcare providers.